BillionToOne operates in the molecular diagnostics industry, focusing on prenatal and oncology testing. The company's proprietary single-molecule next-generation sequencing (smNGS) platform, powered by patented Quantitative Counting Templates (QCTs), enables detection and quantification of genetic targets at the single-DNA-molecule level, addressing the fundamental challenge of sparse disease signals in cell-free DNA (cfDNA). The industry is characterized by rapid technological change, with competition based on brand recognition, product quality, price, and innovation.
Primary competitors in the prenatal market include Illumina (through its subsidiary Verinata), Labcorp, Myriad Genetics, Natera, and Quest Diagnostics. In the oncology market, competitors include Caris Life Sciences, Foundation Medicine (acquired by Roche), Guardant Health, NeoGenomics Laboratories, and Tempus AI. The company's competitive advantages are its four pillars of differentiation: a breakthrough technology platform, category-defining products, ability to deliver rapid growth at scale, and superior efficiency. Management believes the smNGS platform and five years of accumulated data provide a competitive moat that will strengthen over time.
Revenue is generated primarily from sales of molecular diagnostic tests, with more than 90% of revenue in 2025 stemming from reimbursement of prenatal and oncology tests in the United States. The company bills insurance carriers, Medicaid, Medicare, or patients upon delivery of test results. Revenue is recognized at a point in time when test results are delivered to the ordering physician. The company uses an expected value method to estimate variable consideration from third-party payors, considering historical payment trends, contractual arrangements, and current expectations.
The UNITY prenatal product portfolio includes the UNITY Fetal Risk Screen, launched in 2019, which is the first non-invasive prenatal test (NIPT) using cfDNA to provide fetal risk assessment for recessive conditions without requiring a paternal sample. In May 2025, the testing menu was expanded to include up to 14 conditions. The UNITY Aneuploidy Screen, launched in 2020, achieves above 99.7% sensitivity and 99.9% specificity for common trisomies and enables industry-leading positive predictive value of 80% for 22q11.2 microdeletion in average risk pregnancies. More than 75% of UNITY Aneuploidy orders include 22q11.2 optional add-on testing. The UNITY Fetal RhD NIPT, launched in 2020, has been ordered for over 150,000 patients with 100% concordance with neonatal outcomes and sensitivity/specificity of >99.9%. The UNITY Fetal Antigen NIPT, launched in 2022, is the only commercially available test for fetal antigen screening in the United States, offering 100% sensitivity and specificity with a no-call rate of <0.1%. In February 2026, the company launched expanded Red Blood Cell Fetal Antigen NIPT and a first-and-only Platelet Fetal Antigen NIPT, addressing conditions affecting approximately 1.5-2.5% of pregnancies in the U.S.
The Northstar oncology portfolio includes Northstar Select, launched in January 2023, an ultrasensitive liquid biopsy test for therapy selection in stage III or IV cancer patients, with a limit of detection of 0.15% and demonstrated detection of 51% more actionable SNVs and Indels and 109% more CNVs than comparator assays. Northstar Response, also launched in January 2023, is a pan-cancer smNGS-based liquid biopsy test that precisely measures more than 2,200 genomic loci uniquely methylated in cancer, achieving a limit of detection of 0.01%. More than 95% of oncologists who ordered tests in 2025 utilized both Northstar Select and Northstar Response in tandem. In January 2026, the company launched Northstar PGx, and in February 2026, Northstar Select CH. A tissue-free, pan-cancer MRD test is expected to be commercially available in the fourth quarter of 2026.
In November 2025, the company completed its initial public offering, issuing and selling 5,233,765 shares of Class A common stock at $60.00 per share, including full exercise of the underwriters' option for 682,665 shares, generating net proceeds of $286.9 million after deducting underwriting discounts and commissions of $22.0 million and offering expenses of $5.1 million. The company has a debt facility with Oberland Capital with availability of up to $140.0 million, with $50.0 million drawn as of December 31, 2025, and an obligation to sell an additional $30.0 million tranche before March 31, 2026. The company entered into a global partnership with Johnson & Johnson in December 2023 to provide the UNITY Fetal Antigen CTA in the AZALEA Phase 3 clinical trial, and a development and commercialization agreement in July 2025 for a companion diagnostic product, with cumulative upfront fees, milestone payments, and costs not to exceed $13 million. As of December 31, 2025, the company had 713 full-time employees, with 231 sales representatives (177 in prenatal, 54 in oncology).
For the fiscal year ended December 31, 2025, total revenue was $305.112 million 1, compared to $152.582 million 2 in 2024, representing 100% growth. Net income was $7.454 million 3 in 2025, compared to a net loss of $41.570 million 4 in 2024. Gross profit was $208.458 million 5 with a gross margin of 68% 6, compared to $80.915 million 7 and 53% 8 in the prior year. Income from operations was $16.023 million 9 in 2025 versus a loss from operations of $47.146 million 10 in 2024. Adjusted EBITDA was $38.802 million 11 in 2025, compared to negative $31.925 million 12 in 2024.
A primary growth vector is driving increased adoption of existing products in the prenatal and oncology markets. In prenatal, the company sees opportunity for footprint expansion through increasing sales team size, deeper penetration of existing territories, and growth within clinics after initial adoption. In oncology, the commercial efforts have just begun with the field sales team covering only a fraction of the geography, offering significant room for growth via geographical expansion and deeper penetration. The company plans to continue expanding its field sales force systematically, noting the prenatal sales force is less than one-third the size of its largest competitor and the oncology sales force is very small relative to many other liquid biopsy companies.
Another key growth vector is expanding the product portfolio using the smNGS platform. The company is developing a tissue-free, pan-cancer MRD test expected to be commercially available in the fourth quarter of 2026. Longer term, the company believes the smNGS technology could address sensitivity challenges of early-stage cancer detection, with necessary R&D funding included in the five-year strategic plan. The company is also building toward AI-enabled personalized medicine by integrating smNGS molecular data with AI-extracted longitudinal clinical data, aiming to provide personalized treatment recommendations.
The company expects to continue reducing costs per test through automation, optimization of laboratory workflows, supplier negotiations, and assay redesign. Gross margin improved to 68% in 2025 from 53% in 2024, with approximately 86% of the improvement attributed to higher average selling prices and 14% to lower cost per test. Variable costs represented 57% of cost of goods sold in 2025 versus 54% in 2024, while fixed costs were 43% versus 46%. The company anticipates that cost initiatives and leveraging fixed costs should continue to reduce overall cost per test.
The company has entered a lease for a new 220,000 square foot facility in Austin, Texas, expected to commence on or before September 30, 2027, and expiring in June 2043, with an option to extend for an additional seven years. Once fully utilized, the company expects potential testing capacity to be nearly triple current capabilities. The company expects to occupy the facility in 2027 and open for processing commercial samples in 2028. The company continues to integrate AI across operations, including automating sample accessioning, reimbursement processing, and laboratory workflows.
Research and development expenses were $49.384 million 13 for 2025, and the company expects R&D costs to increase in absolute dollars but moderately decline as a percentage of revenue over time. Capital expenditures were $8.881 million 14 in 2025. The company does not disclose specific R&D spending targets, capital expenditure plans, share repurchase authorizations, or dividend policy figures beyond what is stated in the filing. The company has never declared or paid dividends and does not intend to pay cash dividends in the foreseeable future.
The company faces structural headwinds including the inherent variability of the insurance coverage and reimbursement landscape, which makes it difficult to predict amounts ultimately collected for tests. The company estimates revenue at the time a test is provided and records adjustments if cash subsequently received differs. The company also faces risks from potential changes in FDA enforcement of laboratory-developed tests, which could subject operations to more significant regulatory requirements. International markets represented less than 1% of revenue for 2025, limiting geographic diversification.
The company identified material weaknesses in internal control over financial reporting related to an insufficient control environment, lack of effective controls for analyzing certain financial instruments, and inadequate user access controls. These material weaknesses remain unremediated as of the filing date, with remediation efforts ongoing in 2026, including hiring additional personnel, designing controls over user access, and implementing controls for financial instrument transactions.
Management's message emphasizes the company's transformation from an R&D-focused company to a proven commercial organization, highlighting the achievement of net income for the year ended December 31, 2025. Key themes include the four pillars of differentiation (breakthrough technology platform, category-defining products, rapid growth at scale, and superior efficiency), the potential for the UNITY Fetal Antigen CTA to become the first NIPT with a companion diagnostics indication pending successful completion of Johnson & Johnson's AZALEA Phase 3 clinical trial, and the vision of powering AI-enabled personalized medicine. Strategic priorities emphasized for the period ahead include driving increased adoption of existing products in prenatal and oncology markets, building clinical evidence to support favorable coverage and reimbursement, efficiently expanding the product portfolio (including the planned MRD test for commercial availability in the fourth quarter of 2026), deploying AI across the organization to improve efficiency, and leveraging the growing clinical dataset with AI to improve diagnostic utility and enable personalized medicine.
For the fiscal year ended December 31, 2025, total revenue was $305.112 million 15, compared to $152.582 million 16 in 2024. Net income was $7.454 million 17 in 2025 versus a net loss of $41.570 million 18 in 2024. Diluted earnings per share was $0.14 19 in 2025, compared to a diluted loss per share of $4.12 20 in 2024. Income from operations was $16.023 million 21 in 2025 versus a loss from operations of $47.146 million 22 in 2024. Gross profit was $208.458 million 23 with a gross margin of 68% 24 in 2025, compared to $80.915 million 25 and 53% 26 in 2024. Cash and cash equivalents were $495.975 million 27 as of December 31, 2025, compared to $191.477 million 28 as of December 31, 2024. Long-term debt was $57.226 million 29 as of December 31, 2025, compared to $51.481 million 30 as of December 31, 2024. Net cash provided by operating activities was $24.595 million 31 in 2025, compared to net cash used in operating activities of $41.375 million 32 in 2024. The company recorded a net gain on extinguishment of debt of $7.289 million 33 in 2024, with no such gain in 2025. Stock-based compensation expense was $15.915 million 34 in 2025, compared to $8.362 million 35 in 2024. For segment performance, prenatal revenue was $277.105 million 36 in 2025, oncology revenue was $24.953 million 37, and clinical trial support and other services revenue was $3.054 million 38.
The company's revenue is highly dependent on reimbursement from third-party payors, which represented more than 90% of revenue for each of the years ended December 31, 2025 and 2024. If government and commercial payors fail to provide coverage and adequate payment for existing and future tests, revenue and profitability prospects will be harmed. The company has identified material weaknesses in internal control over financial reporting that remain unremediated, pertaining to an insufficient control environment, lack of effective controls for analyzing certain financial instruments (including common stock warrants and debt instruments), and inadequate user access controls. The company faces significant competition from established players with greater financial resources, including Illumina, Natera, Guardant Health, and Foundation Medicine, and may be unable to compete effectively. The company's tests are currently marketed as laboratory-developed tests (LDTs), and future changes in FDA enforcement of LDTs could subject operations to more significant regulatory requirements, potentially requiring premarket clearance or approval. The company has generally incurred losses since inception, with an accumulated deficit of $274.7 million as of December 31, 2025, and may not be able to sustain profitability.
Analysis on 9/28/2026
